^
    Back
    Association details:
    Biomarker:TP53 mutation + Chr del(17p)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Jaypirca (pirtobrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eli Lilly Press Release
    Title:

    Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting

    Published date:
    12/07/2020
    Excerpt:
    Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company...today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)...In the 28 patients with a 17p deletion, TP53 mutation, or both, the ORR was 79% (22/28)...